PGNY240920C35000
- 0.05
- 0.000.00%
Progyny Newsroom
Stephen Neukam Axios Congress Reporter Posts On X "Senate Republicans Just Killed a Bill That Mirrors Trump's Proposal for Universal IVF Access. It Got 51 Votes on the Floor. It Needed 60."
North Dakota Judge Overturns State's Abortion Ban, Making Abortion Legal In The State
Should You Investigate Progyny, Inc. (NASDAQ:PGNY) At US$22.90?
Goldman's 'Goldilocks' Mid-cap Picks That Trade at Reasonable Valuations
Could The Market Be Wrong About Progyny, Inc. (NASDAQ:PGNY) Given Its Attractive Financial Prospects?
CNH Industrial, Parsons and More Join S&P MidCap 400
Here's What Affected Progyny's (PGNY) Share Price in Q2
Do Options Traders Know Something About Progyny (PGNY) Stock We Don't?
Cantor Fitzgerald Reiterates Overweight on Progyny, Maintains $37 Price Target
Cogent Communications To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday
Progyny Is Maintained at Overweight by JP Morgan
Truist Financial Maintains Progyny(PGNY.US) With Buy Rating
Truist Financial analyst Jailendra Singh maintains $Progyny(PGNY.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 37.2% and a total average return of -14.2% over
J.P. Morgan Maintains Progyny(PGNY.US) With Buy Rating, Announces Target Price $31
J.P. Morgan analyst Anne Samuel maintains $Progyny(PGNY.US)$ with a buy rating, and sets the target price at $31.According to TipRanks data, the analyst has a success rate of 47.4% and a total
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Progyny (PGNY) and Health Catalyst (HCAT)
Express News | Progyny Inc : JP Morgan Cuts Target Price to $31 From $41
Top 3 Health Care Stocks That Are Set To Fly This Quarter
The Strong Earnings Posted By Progyny (NASDAQ:PGNY) Are A Good Indication Of The Strength Of The Business
A Quick Look at Today's Ratings for Progyny(PGNY.US), With a Forecast Between $24 to $31
On Aug 13, major Wall Street analysts update their ratings for $Progyny(PGNY.US)$, with price targets ranging from $24 to $31.Barclays analyst Stephanie Davis maintains with a buy rating, and
Progyny: Growth Potential Acknowledged Amid Execution Concerns – Hold Rating Maintained
Progyny (PGNY) Gets a Buy From Barclays